Ribociclib Lowers Risk of Disease Recurrence by 25% for Earl

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Related Keywords

United States , American , Shreeram Aradhye , Dennisj Slamon , Ribociclib Kisqali , Translational Research In Oncology , American Society Of Clinical Oncology Annual Meeting , Clinical Translational Research , Novartis , Global Drug Development , Clinical Oncology Annual , Translational Research , California Los Angeles , Jonsson Comprehensive Cancer Center ,